glp-1 rheumatoid arthritis study Glucagon-like Peptide-1 Receptor Agonists in Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects GLP-1 Receptor Agonists May Improve

The lower abdomen and sides generally offer the most fatty tissue

The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) enrolled thousands of participants and demonstrated that GLP-1 therapy produces meaningful, sustained weight loss across diverse populations, with acceptable safety profiles when used under medical supervision

This medicine is taken once daily at the same time each day

DL: As we look to the future, we intend to measure new populations that include a mix of GLP-1s that have come to market since the initial study time period

While compounded medications are produced in licensed facilities and regulated by state Boards of Pharmacy, they have not been evaluated by the FDA for safety, quality, or efficacy

Published 2022 Jan 10